Senex Biotech

Senex Biotechnology is a drug discovery and development company focused on creating novel therapeutics that target the molecular pathways of cellular senescence and stress response. The company's primary focus is the development of selective small-molecule inhibitors of Cyclin-dependent kinase 8 (CDK8) and Cyclin-dependent kinase 19 (CDK19), which play critical roles in transcription regulation and cancer progression. Their lead programs aim to treat various solid tumors and hematological malignancies by inhibiting the pro-tumorigenic effects of these kinases. Senex leverages its proprietary screening platforms to identify compounds that can overcome drug resistance and improve outcomes in oncology and potentially age-related diseases.